ClinicalTrials.gg
CompletedNCT06313268Updated Oct 10, 2024

Safety of Effivia®, a Bevacizumab Biosimilar

An observational study in Metastatic Colorectal Cancer, Metastatic Cervical Cancer and Non Squamous Non Small Cell Lung Cancer, sponsored by Laboratorios Liomont. Completed at 5 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Laboratorios Liomont · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
83
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Colorectal Neoplasms with a site in Mexico — 8 open to participants now, 10 under way, 6 of them phase 3. Colorectal Neoplasms · Mexico.

Started
2022
with 1 other
Observational
3 of 29
none open now
Registered
21st of 29
by date

Among the 29 studies in Colorectal Neoplasms with a site in Mexico, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 21st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

8 of the 29 studies in Colorectal Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms with a site in Mexico, or all of them as a file.
02

Study summary

This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.

03

Conditions studied

  • Metastatic Colorectal Cancer
  • Metastatic Cervical Cancer
  • Non Squamous Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Naive to bevacizumab, adult patients with metastatic colorectal cancer, metastatic cervical cancer, non-squamous non-small cell lung cancer, and other cancer types where Bevacizumab therapy is indicated.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients, 18 years and older.
  • Patients with colorectal cancer,unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, or epithelial ovarian, fallopian tube, or primary peritoneal cancer naive to bevacizumab therapy (Effivia®).
  • Provide written .

Exclusion criteria

Exclusion Criteria:

  • History of recent surgery or wound healing complications.
  • History of gastrointestinal perforations or fistula.
  • History of renal injury and proteinuria.
  • Recent surgical intervention.
  • Pregnant or nursing women.
  • History of bevacizumab, monoclonal antibodies, or CHO cells-derived products .
  • Other safety concerns or bevacizumab .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
83 participants (actual)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Test group

    Bevacizumab (Effivia®)

    Drug: Bevacizumab Biosimilar MB02

Interventions

  • DrugMB02Studies of MB02MB02 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5 mg/kg to 15 mg/kg in combination with chemotherapy.

    Also known as: Effivia®

06

What researchers measure

Primary outcomes

  1. Adverse events

    Frequency and characteristics of adverse events (serious and non serious)

    Time frame: From date of patient inclusion to the end of Cycle 1 (each cycle is up to six months)

07

Study locations

5 sites
  • UMAE Hospital de Especialidades No. 1
    León, Guanajuato 37320, Mexico
  • Hospital de Gineco-Obstetricia No. 3
    Azcapotzalco, Mexico City 02990, Mexico
  • Hospital de Oncología, UMAE Centro Médico Nacional Siglo XXI
    Cuauhtémoc, Mexico City 06720, Mexico
  • Instituto Nacional de Cancerología
    Tlalpan, Mexico City 14080, Mexico
  • Hospital de Oncología IMSS Puebla
    Puebla, 07200, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2024, 20 months.

Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 20 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Mar 15, 2024
StartActual
Aug 11, 2022
Primary completionActual
Apr 17, 2024
CompletionActual
Sep 2, 2024
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06313268
Lead sponsor
Laboratorios Liomont
Collaborators
Servicios Especializados en Ensayos Clínicos, S.C.
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Aug 11, 2022
Primary completion
Apr 17, 2024
Completion
Sep 2, 2024
Last update
Oct 10, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion